Pharmacokinetics and Pharmacodynamics Practice Questions

Q: When a drug binds to a receptor and causes an action opposite to that of an agonist, what is this called?

Inverse agonist. ### Explanation **1. Why "Inverse Agonist" is Correct:** In pharmacology, receptors often exhibit **constitutive activity**, meaning they produce a baseline biological response even in the absence of a ligand. An **Inverse Agonist** binds to the same receptor as an agonist but stabilizes the inactive form, thereby reducing the constitutive activity. This results in a pharmacological effect that is **directionally opposite** to that of the agonist (negative efficacy). **2. Analysis of Incorrect Options:** * **A. Complete (Full) Agonist:** Binds to the receptor and produces the maximum possible biological response (100% efficacy). * **B. Partial Agonist:** Binds to the receptor but produces a sub-maximal response, even at full receptor occupancy. It acts as an antagonist in the presence of a full agonist. * **D. Neutral Antagonist:** Binds to the receptor but has **zero intrinsic activity**. It does not produce a response of its own; it simply blocks the agonist from binding. It does not affect the constitutive activity. **3. NEET-PG High-Yield Clinical Pearls:** * **Classic Examples of Inverse Agonists:** * **Beta-carbolines** (at GABA-A receptors): Cause anxiety and convulsions (opposite to Benzodiazepines). * **Famotidine** (H2 receptors). * **Losartan** (AT1 receptors). * **Naloxone** (at Mu-opioid receptors). * **Key Distinction:** While an antagonist has **zero** efficacy, an inverse agonist has **negative** efficacy. * **Concept Check:** If a receptor has no constitutive activity, an inverse agonist will behave exactly like a neutral antagonist.

Q: When a drug binds to a receptor and causes an action opposite to that of an agonist, it is called as:

Inverse agonist. ### Explanation **Correct Answer: C. Inverse Agonist** The concept of drug-receptor interaction is based on the **Two-State Model**. Receptors exist in an equilibrium between an **inactive (Ri)** and an **active (Ra)** state. Even in the absence of a ligand, some receptors are in the Ra state, producing a baseline "constitutive activity." * **Inverse Agonists** have a higher affinity for the **inactive (Ri)** state. By binding to and stabilizing the inactive form, they reduce the constitutive activity to below-baseline levels, effectively producing an effect **opposite** to that of an agonist. * *Example:* Beta-carbolines act as inverse agonists at GABA-A receptors, causing anxiety and convulsions (opposite to the sedative effect of GABA). **Analysis of Incorrect Options:** * **A. Complete (Full) Agonist:** Binds to the active state (Ra) and produces the maximum possible biological response (100% efficacy). * **B. Partial Agonist:** Binds to both states but has a slight preference for Ra. It produces a sub-maximal response regardless of concentration and can act as an antagonist in the presence of a full agonist. * **D. Neutral Antagonist:** Has equal affinity for both Ri and Ra states. It does not change the baseline activity but prevents an agonist from binding. **High-Yield Clinical Pearls for NEET-PG:** * **Efficacy vs. Potency:** Efficacy (Intrinsic Activity) is the maximum effect a drug can produce; Potency is the amount of drug needed to produce a certain effect. * **Intrinsic Activity (α) Values:** * Full Agonist: α = 1 * Antagonist: α = 0 * Partial Agonist: α is between 0 and 1 * Inverse Agonist: α is negative (e.g., -1) * **Common Example:** Naloxone is a competitive antagonist, while many drugs previously thought to be antagonists (like Propranolol) are now classified as inverse agonists.

Q: The pharmacokinetic properties of a new drug are being studied in normal volunteers during phase I clinical trials. The volume of distribution and clearance determined in the first subject are 40 L and 2.0 L/hour, respectively. What is the approximate half-life of the drug in this subject?

14 hours. ### Explanation **1. Why Option C is Correct** The relationship between the half-life ($t_{1/2}$), volume of distribution ($V_d$), and clearance ($CL$) of a drug is defined by the following first-order kinetics formula [1]: $t_{1/2} = rac{0.693 \times V_d}{CL}$ **Calculation:** * Given $V_d = 40\text{ L}$ * Given $CL = 2.0\text{ L/hr}$ * $t_{1/2} = rac{0.693 \times 40}{2.0}$ * $t_{1/2} = 0.693 \times 20$ * $t_{1/2} = 13.86\text{ hours} \approx \mathbf{14\text{ hours}}$ The half-life is directly proportional to the volume of distribution (how widely the drug spreads in the body) and inversely proportional to the clearance (how fast the body removes the drug) [2]. **2. Why Other Options are Incorrect** * **Option A (2 hours):** This would occur if the clearance was much higher (approx. $14\text{ L/hr}$) or the $V_d$ much lower. * **Option B (6 hours):** This is a common distractor resulting from calculation errors or forgetting the $0.693$ constant. * **Option D (21 hours):** This value would be reached if the $V_d$ was $60\text{ L}$ or the clearance was reduced to $1.3\text{ L/hr}$. **3. Clinical Pearls for NEET-PG** * **Steady State:** It takes approximately **4 to 5 half-lives** for a drug to reach steady-state concentration ($C_{ss}$) during continuous dosing. * **Elimination:** Similarly, it takes 4 to 5 half-lives for a drug to be effectively eliminated from the body (94–97% removal). * **$V_d$ and Dialysis:** Drugs with a very high $V_d$ (e.g., Digoxin, Chloroquine) are sequestered in tissues and cannot be efficiently removed by hemodialysis. * **Clearance:** This is the most important parameter in determining the **Maintenance Dose**, whereas $V_d$ determines the **Loading Dose** [3].

Q: Which of the following statements regarding Cytochrome P450 is FALSE?

Found only in bone marrow. **Explanation:** **Why Option A is the correct (False) statement:** Cytochrome P450 (CYP450) enzymes are **not** found only in the bone marrow. In fact, they are most abundantly expressed in the **liver** (the primary site of drug metabolism), followed by the enterocytes of the small intestine. While they exist in various extrahepatic tissues like the kidneys, lungs, and skin, their presence in the bone marrow is minimal and certainly not exclusive. **Analysis of other options:** * **Option B (CYP3A4 is the most common isoform):** This is true. CYP3A4 is the most abundant isoform in the liver and is responsible for metabolizing approximately 50% of all clinically used drugs. * **Option C (Participate in Phase 1 reactions):** This is true. CYP450 enzymes are the primary mediators of Phase 1 reactions, specifically **oxidation**, reduction, and hydrolysis, which aim to make drugs more polar. * **Option D (Present in Smooth Endoplasmic Reticulum):** This is true. These enzymes are membrane-bound hemoproteins located primarily in the **Smooth Endoplasmic Reticulum (SER)** of hepatocytes. When liver tissue is homogenized, these SER fragments form "microsomes," which is why they are often called microsomal enzymes. **High-Yield Clinical Pearls for NEET-PG:** * **Inducers (Increase metabolism):** Phenytoin, Rifampin, Carbamazepine, Griseofulvin, Smoking (Mnemonic: **GPRS Cell Phone**). * **Inhibitors (Decrease metabolism):** Erythromycin, Ketoconazole, Cimetidine, Valproate, Grapefruit juice (Mnemonic: **VITAMIN K**). * **Genetic Polymorphism:** Most commonly seen with **CYP2D6** (affects codeine and metoprolol metabolism). * **Non-Microsomal Enzymes:** These include Alcohol dehydrogenase, MAO, and Xanthine oxidase; unlike CYP450, these are **not** inducible.

Q: Which of the following is an ionotropic receptor?

Nicotinic cholinergic receptor. **Explanation:** Receptors are classified into four major types based on their structure and signaling mechanism. **Ionotropic receptors** (Ligand-gated ion channels) are transmembrane proteins that open or close in response to the binding of a chemical messenger, allowing the rapid flow of ions across the cell membrane. **Why Option B is Correct:** The **Nicotinic Cholinergic Receptor (nAChR)** is a classic example of an ionotropic receptor. It is a pentameric structure that, upon binding with Acetylcholine, undergoes a conformational change to open a central pore. This allows the influx of **Sodium (Na+)** and efflux of **Potassium (K+)**, leading to rapid depolarization. These are found at the neuromuscular junction (NMJ) and autonomic ganglia. **Why Other Options are Incorrect:** * **A. Muscarinic Cholinergic Receptor:** These are **G-Protein Coupled Receptors (GPCRs)** or metabotropic receptors. They act via second messengers (like IP3/DAG or cAMP) and are slower than ionotropic receptors. * **C. Glucocorticoid Receptor:** These are **Intracellular/Nuclear receptors**. They act as ligand-activated transcription factors that regulate gene expression in the nucleus. * **D. Insulin Receptor:** This is an **Enzyme-linked receptor** (specifically, a Receptor Tyrosine Kinase). Binding of insulin leads to autophosphorylation of tyrosine residues. **High-Yield Clinical Pearls for NEET-PG:** * **Fastest Receptors:** Ionotropic receptors (milliseconds) > GPCRs (seconds) > Enzyme-linked (minutes/hours) > Nuclear receptors (hours/days). * **Other Ionotropic Examples:** GABA-A (Chloride channel), Glycine, 5-HT3 (the only ionotropic Serotonin receptor), and NMDA/AMPA receptors. * **Pharmacogenomics Link:** Mutations in the subunits of the nicotinic receptor can lead to conditions like Congenital Myasthenic Syndromes.

Q: A patient with normal renal function has received a daily maintenance dose of digoxin for 2 weeks. If the dosage is changed, in approximately how long would the new steady-state plasma digoxin concentration be achieved?

1 week. The time required to reach a new steady-state concentration (Css) after a change in dosage is determined by the drug's **half-life ($t_{1/2}$)** [2]. It is a fundamental pharmacokinetic principle that steady state is achieved after **4 to 5 half-lives** of a drug [2]. Digoxin has a half-life of approximately **36 to 40 hours** (roughly 1.5 days) in a patient with normal renal function [1]. Therefore, approximately **1 week** is required to reach the new steady state. Digoxin has a **narrow therapeutic index** (0.5–2 ng/mL), plasma levels should only be measured after steady state is reached (i.e., after 1 week) to ensure accuracy [1].

Q: Exogenous adrenaline is metabolized by:

COMT. **Explanation:** The metabolism of catecholamines (Adrenaline, Noradrenaline, and Dopamine) involves two primary enzymes: **Catechol-O-methyltransferase (COMT)** and **Monoamine oxidase (MAO)**. **Why COMT is correct:** COMT is responsible for the O-methylation of catecholamines. When adrenaline is administered **exogenously**, it is primarily metabolized by COMT in the liver and kidneys. COMT acts on the catechol ring, converting adrenaline into metanephrine. In contrast, MAO is primarily located in the mitochondria of neuronal terminals and is more significant for the reuptake and degradation of endogenous (neuronal) catecholamines. **Why other options are incorrect:** * **AChE (Acetylcholinesterase):** This enzyme is specific for the rapid hydrolysis of **Acetylcholine** at cholinergic synapses. It has no role in catecholamine metabolism. * **Decarboxylase (L-amino acid decarboxylase):** This enzyme is involved in the **synthesis** (not metabolism) of catecholamines, specifically converting L-Dopa to Dopamine. * **Acetyl transferase:** This enzyme is involved in the metabolism of drugs like Isoniazid, Hydralazine, and Procainamide (via acetylation), but not adrenaline. **High-Yield Clinical Pearls for NEET-PG:** * **VMA (Vanillylmandelic acid):** The final common metabolic product of both adrenaline and noradrenaline. Elevated urinary VMA levels are a diagnostic marker for **Pheochromocytoma**. * **Metanephrines:** These are the intermediate metabolites (via COMT). Measuring plasma free metanephrines is currently considered the most sensitive screening test for Pheochromocytoma. * **COMT Inhibitors:** Drugs like **Entacapone** and **Tolcapone** are used in Parkinson’s disease to prevent the peripheral breakdown of Levodopa.

Q: In the given pharmacodynamic curve, point A corresponds to:

ED50. ***ED50*** - Point A on the **dose-response curve** represents the dose that produces **50% of the maximum response**, which is the definition of **ED50**. - It is located at the **intersection** of the 50% response level with the curve, read directly from the **x-axis (dose axis)**. *Potency* - **Potency** refers to the overall **position of the curve** on the x-axis, not a specific point like A. - A more potent drug has its entire curve **shifted to the left**, requiring lower doses for the same effects. *Efficacy* - **Efficacy** represents the **maximum response** achievable by a drug, shown as the **plateau height** of the curve. - Point A is on the **dose axis**, not at the maximum response level, so it cannot represent efficacy. *LD50* - **LD50** is the **lethal dose** for 50% of the population, derived from **quantal dose-response curves**. - This parameter is used for **toxicity studies**, not therapeutic effect measurements shown in graded dose-response curves.

Q: Receptor-mediated action is not seen in which of the following?

Antacids. **Explanation:** The core concept tested here is the **mechanism of drug action**. Most drugs act by binding to specific **receptors** (proteins), but some exert their effects through non-receptor-mediated physical or chemical processes. **Why Antacids are the correct answer:** Antacids (e.g., Aluminum hydroxide, Magnesium hydroxide) act through a **purely chemical neutralization reaction**. They are weak bases that react directly with gastric hydrochloric acid (HCl) to form salt and water, thereby increasing the pH of the gastric contents. This process does not involve binding to any cellular receptor. **Analysis of Incorrect Options:** * **Antipsychotics:** These drugs act primarily by blocking **Dopamine (D2) receptors** in the mesolimbic pathway of the brain. * **Benzodiazepines:** These act as positive allosteric modulators of the **GABA-A receptor** complex, increasing the frequency of chloride channel opening. * **Alcohol (Ethanol):** While alcohol has complex effects, its primary sedative-hypnotic actions are mediated through the enhancement of **GABA-A receptors** and inhibition of NMDA glutamate receptors. **High-Yield Clinical Pearls for NEET-PG:** Other examples of **Non-Receptor Mediated Mechanisms** frequently asked in exams include: 1. **Physical Action:** Adsorbents (Activated Charcoal), Osmotic laxatives (Lactulose, Magnesium sulfate), and Osmotic diuretics (Mannitol). 2. **Chemical Action:** Chelating agents (EDTA, Dimercaprol) which bind to heavy metals. 3. **Counterfeit Incorporation:** Purine/Pyrimidine analogues (Anticancer drugs) that get incorporated into DNA. 4. **Enzyme Inhibition:** Drugs like Neostigmine (AChE) or Captopril (ACE).

Question 1

A U-shaped dose-response curve is typically observed with which of the following?

Accepted Answer

Vitamins

Answer

Anti-cancer drugs

Answer

Steroids

Answer

Chelators

Question 2

When a drug binds to a receptor and causes an action opposite to that of an agonist, what is this called?

Accepted Answer

Inverse agonist

Answer

Complete Agonist

Answer

Partial Agonist

Answer

Neutral antagonist

Question 3

When a drug binds to a receptor and causes an action opposite to that of an agonist, it is called as:

Accepted Answer

Inverse agonist

Answer

Complete agonist

Answer

Partial agonist

Answer

Neutral agonist

Question 4

The pharmacokinetic properties of a new drug are being studied in normal volunteers during phase I clinical trials. The volume of distribution and clearance determined in the first subject are 40 L and 2.0 L/hour, respectively. What is the approximate half-life of the drug in this subject?

Accepted Answer

14 hours

Answer

2 hours

Answer

6 hours

Answer

21 hours

Question 5

Which of the following statements regarding Cytochrome P450 is FALSE?

Accepted Answer

Found only in bone marrow

Answer

CYP3A4 is the most common isoform

Answer

Participate in Phase 1 Xenobiotic reactions

Answer

They are present in Smooth Endoplasmic reticulum within cells

Question 6

Which of the following is an ionotropic receptor?

Accepted Answer

Nicotinic cholinergic receptor

Answer

Muscarinic cholinergic receptor

Answer

Glucocorticoid receptor

Answer

Insulin receptor

Question 7

A patient with normal renal function has received a daily maintenance dose of digoxin for 2 weeks. If the dosage is changed, in approximately how long would the new steady-state plasma digoxin concentration be achieved?

Accepted Answer

1 week

Answer

2 days

Answer

2 weeks

Answer

4 weeks

Question 8

Exogenous adrenaline is metabolized by:

Accepted Answer

COMT

Answer

AChE

Answer

Decarboxylase

Answer

Acetyl transferase

Question 9

In the given pharmacodynamic curve, point A corresponds to:

Accepted Answer

ED50

Answer

Potency

Answer

Efficacy

Answer

LD50

Question 10

Receptor-mediated action is not seen in which of the following?

Accepted Answer

Antacids

Answer

Alcohol

Answer

Antipsychotics

Answer

Benzodiazepines

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?